LUVOX (Fluvoxamine): Fluvoxamine REDUCED HOSPITALIZATIONS BY 67% and decreased death by 91%, reported in patients who took and tolerated the fluvoxamine 100 mg twice daily for 10 days, per October 27 Lancet Global Health . The trial was initiated on June 2, 2020, with the current protocol reporting randomization to fluvoxamine from Jan 20 to Aug 5, 2021, when the trial arms were stopped for superiority. 741 patients were allocated to fluvoxamine and 756 to placebo. Investigators monitored participants for 28 days after treatment. In the placebo group, 119 of 756 patients, or 15.7 percent, developed complications requiring hospitalization or more than six hours of emergency care. In comparison, 79 of 741, or 10.7 percent, of fluvoxamine-treated patients got that sick. In this trial taking fluvoxamine cut emergency visits and hospitalization by 32 percent Fluvoxamine cut serious complications in patients who took at least 80 percent of their doses...
This is a blog by Kaleem Mohammed, PhD, for those who want to understand little more about health conditions and medications. He is a community pharmacist and chronic disease educator for Salt Lake County Health dept. As an Asst. Prof at University of Utah, he taught pharmacology to MD, PA and PharmD students. His Hypoxia Inducible Factor-1 research has been cited by Drs. Gregg Samenza/EJ Corey (Nobel, 2019/1990)